• Login
    View Item 
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of ChristieCommunitiesTitleAuthorsIssue DateSubmit DateSubjectsThis CollectionTitleAuthorsIssue DateSubmit DateSubjectsProfilesView

    My Account

    LoginRegister

    Local Links

    The Christie WebsiteChristie Library and Knowledge Service

    Statistics

    Display statistics

    Development of synthetic promoters for radiation-mediated gene therapy.

    • CSV
    • RefMan
    • EndNote
    • BibTex
    • RefWorks
    Authors
    Marples, B
    Scott, S D
    Hendry, Jolyon H
    Embleton, M J
    Lashford, Linda S
    Margison, Geoffrey P
    Affiliation
    Cancer Research Campaign Section of Genome Damage and Repair, Paterson Institute for Cancer Research, Manchester, UK.
    Issue Date
    2000-03
    
    Metadata
    Show full item record
    Abstract
    Exposure of cells to ionising radiation results in the activation of specific transcriptional control (CArG) elements within the early growth response 1 (Egr1) gene promoter, leading to increased gene expression. As part of a study investigating the potential use of these elements in radiation-controlled gene therapy vectors, we have incorporated their sequences into a synthetic gene promoter and assayed for the ability to induce expression of a downstream reporter gene following irradiation. In vector-transfected MCF-7 breast adenocarcinoma cells, the synthetic promoter was more effective than the wild-type Egr1 counterpart in up-regulating expression of the reporter gene after exposure to a single 5 Gy dose, and equally effective as the wild-type in U87-MG glioma cells. The level of gene expression achieved using the synthetic promoter was dependent on the inducing radiation dose for both U87-MG and MCF-7 cells, being maximal at 3 Gy and decreasing at 5 and 10 Gy. Furthermore, induction could be repeated by additional radiation treatments. The latter indicates that up-regulation should be additive during fractionated radiotherapy schedules. To demonstrate the potential clinical benefit of such an approach, the synthetic promoters were also shown to drive expression of the herpes simplex virus thymidine kinase gene, leading to enhanced cell killing in the presence of the prodrug ganciclovir (GCV) when compared with cells treated with radiation alone. Our results demonstrate that the synthetic promoter is responsive to low doses of ionising radiation and therefore isolated CArG elements function as radiation-mediated transcriptional enhancers outside their normal sequence context. The continued development and optimisation of such radiation-responsive synthetic promoters is expected to make a valuable contribution to the development of future radiation-responsive vectors for cancer gene therapy.
    Citation
    Development of synthetic promoters for radiation-mediated gene therapy. 2000, 7 (6):511-7 Gene Ther.
    Journal
    Gene Therapy
    URI
    http://hdl.handle.net/10541/86683
    DOI
    10.1038/sj.gt.3301116
    PubMed ID
    10757025
    Type
    Article
    Language
    en
    ISSN
    0969-7128
    ae974a485f413a2113503eed53cd6c53
    10.1038/sj.gt.3301116
    Scopus Count
    Collections
    All Christie Publications
    All Paterson Institute for Cancer Research

    entitlement

    Related articles

    • Gene therapy vectors containing CArG elements from the Egr1 gene are activated by neutron irradiation, cisplatin and doxorubicin.
    • Authors: Greco O, Powell TM, Marples B, Joiner MC, Scott SD
    • Issue date: 2005 Jul
    • Optimizing radiation-responsive gene promoters for radiogenetic cancer therapy.
    • Authors: Scott SD, Joiner MC, Marples B
    • Issue date: 2002 Oct
    • Hypoxia- and radiation-activated Cre/loxP 'molecular switch' vectors for gene therapy of cancer.
    • Authors: Greco O, Joiner MC, Doleh A, Powell AD, Hillman GG, Scott SD
    • Issue date: 2006 Feb
    • [HSV-TK gene therapy of lung adenocarcinoma xenografts using a hypoxia/radiation dual-sensitive promoter].
    • Authors: Wang WD, Chen ZT, Li DZ, Duan YZ, Wang ZX, Cao ZH
    • Issue date: 2004 Jul
    • Gene therapy for prostate cancer: toxicological profile of four HSV-tk transducing adenoviral vectors regulated by different promoters.
    • Authors: Ebara S, Shimura S, Nasu Y, Kaku H, Kumon H, Yang G, Wang J, Timme TL, Aguilar-Cordova E, Thompson TC
    • Issue date: 2002
    DSpace software (copyright © 2002 - 2025)  DuraSpace
    Quick Guide | Contact Us
    Open Repository is a service operated by 
    Atmire NV
     

    Export search results

    The export option will allow you to export the current search results of the entered query to a file. Different formats are available for download. To export the items, click on the button corresponding with the preferred download format.

    By default, clicking on the export buttons will result in a download of the allowed maximum amount of items.

    To select a subset of the search results, click "Selective Export" button and make a selection of the items you want to export. The amount of items that can be exported at once is similarly restricted as the full export.

    After making a selection, click one of the export format buttons. The amount of items that will be exported is indicated in the bubble next to export format.